Background: There is significant evidence that dose tapering of biologics can be safe and effective in rheumatoid arthritis (RA), as advocated by both EULAR and ACR guidelines. Systematic identification of patients suitable to taper, initiating tapering and monitoring disease control thereafter, require additional resources. We undertook an audit to assess the number of patients with RA who had undergone tapering at The University of South Manchester Rheumatology Department. We also explored the barriers to adopting tapering in rheumatology services, through a multi-site survey. Methods: Audit: 50 patients with RA on a biologic agent were randomly identified through repeat prescription requests. Electronic notes were reviewed to capture data on disease activity scores (DAS28) and steroid use. Eligibility for tapering was defined as DAS28 remission (<2.6) or low disease activity (<3.2 with no swollen joints) for a minimum of six months whilst receiving ¼ < 5mg oral prednisolone daily and no parenteral steroid. The audit standard was defined that all patients eligible should have been considered for dose tapering and a reason documented if this was not implemented. Survey: Representatives from nine rheumatology services across Greater Manchester (members of a Biologics Cost Saving Working Group) were invited to participate in an email survey exploring barriers to implementing biologic dose tapering. Results: Of the 50 audited patients, 29 (58%) were eligible for dose tapering and of these, one (3%) had been tapered. Of the 28 eligible patients who had not been tapered, none had a documented reason for not tapering. The most common reason for ineligibility was a DAS28 score >3.2 (12 of 21 patients). Eight (89%) of the invited rheumatology services participated in the survey. One (13%) site had started a tapering initiative. Four (50%) stated that lack of staffing or sustainable infrastructure was the main barrier to implementing tapering. All departments felt they would require additional staff to facilitate a tapering scheme; eight (100%), six (75%), five (63%) and two (25%) felt additional nursing, pharmacy, administrative and medical staff would be required respectively. Three (38%) departments felt that arrangement of and agreement on a gainshare was a barrier to implementing change. Conclusion: Evidence exists that biologic tapering can be safe and effective. The cost savings from tapering across large cohorts of patients should result in a net financial gain, however the resource burden will be borne by the providers facilitating the change. This audit has shown that dose tapering amongst RA patients is low. The survey identifies the main perceived barriers to systematic tapering initiatives are the availability of resources within departments compounded by a lack of suitable gain-share arrangements between commissioners and providers. NHS England supports the establishment of appropriate financial arrangements to incentivise provider to maximise opportunities to realise savings. Disclosures: C.A. has received speaker fees from Biogen. J.L., B.P., S.C-K., J.F., R.H., V.H., A.L. D.R., S.W. and S.H. have declared no conflicts of interest. Background: The aim of fast track (FT) pathway in GCA is to reduce numbers of negative outcomes as sight loss and subsequently loss of independence and mobility which is associated with increase health care use and cost. The role of ultrasound in evaluating patients with GCA has been very promising. Methods: We have conducted a retrospective cohort analysis of patients who referred to our FT GCA clinic. A cohort of patients with a new or flare of GCA diagnosis was identified between August 2016 and September 2017. Diagnosis of GCA using the FT approach was made based on clinical examination, laboratory results and USS findings. Presence of hypoechoic ring around the vessel wall (non-compressible halo sign) was considered as a positive US finding. Results: During the evaluation period, 123 patients were referred to our FT clinic. Mean age was 70 and median age was 72 years old (STD 11). 79% of these patients were females. The majority of these patients (82) were reviewed within one working day in the FT clinic with a median of one day (IQR 2). 16 were diagnosed with GCA, two patients with large vessel vasculitis, two patients with PMR and three patients had flare of their previous PMR. 121 patients referred from the Southend area of which 93 from GP surgeries. 107 patients underwent USS examinations the same day of their review of which 18 were positive. For 16 patients USS examination was not required based on clinical assessment. Only eight biopsies were performed of which four were positive for GCA. Mean time of performing a temporal artery biopsy was seven days and median of five days. One patient was presented with 3 rd nerve palsy and one with diplopia. No sight loss patients contributable to GCA were observed in this study. No hospital admissions required for these patients. Conclusion: Our data indicate that the FT pathway significantly contribute to the quick, secure and prompt diagnosis of GCA. The FT approach consists of a quick evaluation for most of the patients within 24 hours and immediate initiation of treatment. The low number of biopsies performed in our GCA patients was due to the fact that USS replaced biopsy as the main investigational method. Biopsy is considered in patients who have negative or inconclusive USS findings. For GCA, it's been established before that a secondary care fast-track referral pathway, combined with GP education, reported a significant reduction in the number of patients experiencing permanent sight loss compared to those going through usual care, which also contributes to a cost-effective practice as reducing need of admission and use of other than rheumatologic resources as emergency departments. Disclosures: The authors have declared no conflicts of interest. Methods: This was a prospective study. The treatment arm was the HIP where patients were offered an education session (through a local arthritis support charity), and attended a dedicated biosimilar switching clinic staffed by a rheumatology consultant, registrar and specialist pharmacist. Patients were contacted before their next enbrel delivery date and allocated an appointment in the dedicated clinic to switch them to benepali. At this appointment, a decision was made in partnership with the patient to switch them and they were enrolled into iii68 
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